When was Exegenesis Bio founded?

Exegenesis Bio was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Exegenesis Bio located?

Exegenesis Bio is headquartered in Philadelphia, United States.

Who is the current CEO of Exegenesis Bio?

Zhenhua Wu of Exegenesis Bio. They have also founded 1 company.

How many employees does Exegenesis Bio have?

As of Mar 31, 2026, the latest employee count at Exegenesis Bio is 17.

Is Exegenesis Bio a funded company?

Exegenesis Bio is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 21, 2019.

When was the latest funding round of Exegenesis Bio?

Exegenesis Bio's latest funding was a $***** Series B round on Jun 23, 2021, with participation from 5 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $336M in funding in 2026 to date.

Where does Exegenesis Bio rank among its competitors?

Exegenesis Bio ranks 922nd amongst 3185 active competitors, of which 1096 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of Exegenesis Bio?

Exegenesis Bio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Exegenesis Bio - 2026 Company Profile, Team, Funding & Competitors

Exegenesis Bio is a series B company based in Philadelphia (United States), founded in 2019 by Lijun Wang and Zhenhua Wu. It operates as a Developer of cell and gene therapies to treat multiple diseases. Exegenesis Bio has raised $120M in funding from investors like Legend Capital, K2VC and hillhousecapitalgroup.com. The company has 3185 active competitors, including 1096 funded and 796 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Developer of cell and gene therapies to treat multiple diseases. The company has developed AAVarta AAV capsid in silico evolution discovery platform and Constalllation DNA expression cassette design platform to develop genetic medicines for eye, CNS, and liver-directed diseases.

Website: exegenesisbio.com
Social
Email ID: *****@exegenesisbio.com

Key Metrics

Founded Year

2019

Location

Philadelphia, United States

Stage

Series B

Total Funding

$120M in 3 rounds

Latest Funding Round

Series B, Jun 23, 2021, $*****

Investors

Legend Capital & 11 more

Ranked

922^nd among 3185 active competitors

Employee Count

17 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 1012 more

View Exegenesis Bio's full profile

Exegenesis Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Exegensis Bio Co CIN: 861333828 , United States, Active	Feb 11, 2022	-	12 (As on Dec 31, 2024)	-

Exegenesis Bio has raised a total funding of $120M over 3 rounds. Its first funding round was on Oct 21, 2019. Its latest funding round was a Series B round on Jun 23, 2021 for $*****. 5 investors participated in its latest round. Exegenesis Bio has 12 institutional investors.

Here is the list of recent funding rounds of Exegenesis Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 23, 2021	3793445	Series B	3853317	8558024	6538157	3782350
Aug 07, 2020	6666133	Series B	7321201	9042781	7168852	BioTrack Capital & 3 more
Oct 21, 2019	1312078	Series A	1165737	2929360	K2VC	Kaitai Capital Management & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Exegenesis Bio's funding rounds and investors

The founders of Exegenesis Bio are Lijun Wang and Zhenhua Wu. Zhenhua Wu is the CEO of Exegenesis Bio.

Here are the details of Exegenesis Bio's key team members:

Lijun Wang: Co-Founder & Chief Technology Officer of Exegenesis Bio.
Contact Info: 1 email address
Zhenhua Wu: Co-Founder & CEO of Exegenesis Bio.
Contact Info: 1 email address

View details of Exegenesis Bio's Founder profiles and Board Members

Exegenesis Bio's employee count trend

Exegenesis Bio has 17 employees as of Mar 26. Here is Exegenesis Bio's employee count trend over the years:

Uncover Exegenesis Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Exegenesis Bio include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Exegenesis Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	HBM Healthcare Investments, Orbimed & 6 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
922nd	Exegenesis Bio 2019, Philadelphia (United States), Series B	Developer of cell and gene therapies to treat multiple diseases	$120M	Temasek, LYFE Capital & 10 others	43/100